Sadya Khan

Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

Bernard Escudier, Camillo Porta, Petri Bono et al. · Journal of Clinical Oncology · 2014 · 439 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin

G. M. Kabir Uddin, D. Shoeb, Susannah Solaiman et al. · Journal of Viral Hepatitis · 2009 · 110 citations

Veterinary Medicine, Health Sciences, Infectious Diseases +14

Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310.

Bernard Escudier, Camillo Porta, Petri Bono et al. · Journal of Clinical Oncology · 2012 · 67 citations

Medicine, Oncology, Pharmacotherapy +13

Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310.

Bernard Escudier, Camillo Porta, Petri Bono et al. · Journal of Clinical Oncology · 2012 · 29 citations

Medicine, Oncology, Pharmacotherapy +13

Multiple drug resistant typhoid fever outbreak in Kashmir Valley.

M A Kamili, Gulam Rusul Rahmat Ali, M Y Shah et al. · PubMed · 1993 · 17 citations

Veterinary Medicine, Infectious Diseases, Microbiology +17